Nephrology

Host: Mikhail Kosiborod, MD Guest: Stephen J. Greene, MD, FACC, FHFSA Patients with CKD or heart failure face the risk of developing hyperkalemia, and healthcare providers often experience clinical inertia in their treatment. Join the experts as they explore chronic hyperkalemia management, and the role of potassium binders.

Host: Jörg Latus, MD Guest: Chee Kay Cheung, MBCHB, MRCP, PHD Because renal biopsy is required for diagnosis, providers must be able to identify the histopathological characteristics of IgA nephropathy and implement a systemic diagnostic approach. In addition, the mechanisms of action of some IgAN therapies may offer advantages over others in targeting specific pathways i

Guest: Jörg Latus, MD Patients with advanced kidney disease undergoing dialysis are frequently affected by the symptom clusters of chronic kidney disease-associated pruritus, or CKD-aP. These symptoms have the potential to significantly diminish patients’ quality of life by affecting sleep, mental health, and more. This activity reviews best practices for communicating wit

Host: Jörg Latus, MD Guest: Sydney Tang, MBBS, MD In this review of clinical trial results, experts cover the latest data in IgA nephropathy and discuss how their application can improve outcomes for your patients. Studies presented include SPARTAN, SPARTACUS, and the PROTECT open-label extension. Throughout this conversation, faculty also consider the anticipated updates

Host: Jürgen Floege, MD Guest: Jonathan Barratt, PhD Given that IgA nephropathy is a leading cause of kidney failure, early diagnosis and treatment are essential. In the landscape of the many evolving treatment guidelines, how can nephrologists apply emerging evidence and utilize newer therapies to achieve proteinuria remission and maintain eGFR to improve the outcomes of

Host: James Burton, DM, FRCP Guest: Carol Pollock, AO, MBBS, PhD, FRACP, FAHMS Patients with chronic kidney disease may be experiencing severe itch, known as CKD-associated pruritus (CKD-aP). Itching and related symptoms, such as reduced sleep and depression, may be causing a significant negative impact on their quality of life. Join our experts as they use real-world pati

Host: Raymond Townsend, MD Guest: Melissa Magwire, RN, MSN, CDE Guest: Michael Weber, MD The outcomes of large clinical trials such as EMPA-REG have demonstrated that SGLT2 inhibitors are effective, but they do more than lower blood sugar and improve A1c. Similar to statins a long time ago, SGLT2 inhibitors offer many advantages for patients with potential atherosclerot

Host: Stefan H. Jacobson, MD, PhD Guest: Carlos Narváez Mejía, MD Chronic kidney disease-associated pruritus (CKD-aP) is an underreported and underdiagnosed condition that affects a significant proportion of patients with advanced kidney disease undergoing dialysis. But with the approval of difelikefalin, many patients have experienced symptom improvement not only in the

Guest: David Wheeler, MB, CHB, MD, FRCP Hyperkalemia is a common complication in patients on renin-angiotensin-aldosterone system inhibitor (RAASi) therapy. Join Dr. David Wheeler as he explores strategies for managing hyperkalemia while optimizing treatment benefits. Learn about patient-centered communication techniques, risk factors, and treatment options. Discover the impo

Guest: David J. Maron, MD Explore the future of cholesterol management with cutting-edge pharmacologic therapies and the latest research on lipid-lowering treatments. Understand the transformative impact of AI in primary cardiovascular disease prevention, as highlighted by groundbreaking trials like TRANSFORM. Stay informed on how emerging therapies can help patients achieve